Helsinn announces the appointment of Dr Melanie Rolli as Group Chief Executive Officer Helsinn announces the appointment of Dr Melanie Rolli as Group Chief Executive Officer - Giorgio Calderari appointed Vice Chairman of the Board Lugano, Switzerland, January 9, 2023 - Helsinn Group...

Farma Mondo Group and Helsinn sign exclusive partnership to commercialize AKYNZEO® in the Baltic region Farma Mondo Group and Helsinn sign exclusive partnership to commercialize AKYNZEO® in the Baltic region CHIASSO, Switzerland and LUGANO, Switzerland – November 28, 2022 – Farma Mondo Group, a...

Helsinn appoints Dr Melanie Rolli as Group Chief Operating Officer Helsinn appoints Dr Melanie Rolli as Group Chief Operating Officer Lugano, Switzerland, May 19, 2022 – Helsinn Group, a fully integrated, global biopharma company with a diversified pipeline of...

Helsinn Group and BridgeBio Pharma Announce Update to Strategic Collaboration to Develop, Manufacture and Commercialize Infigratinib in Oncology Indications in the U.S. Helsinn Group and BridgeBio Pharma Announce Update to Strategic Collaboration to Develop, Manufacture and Commercialize Infigratinib in Oncology Indications in the U.S. Helsinn gains an exclusive...

Helsinn Launches Fully Integrated Targeted Therapy (FITT) Strategy and Announces Leadership and Structural Changes Helsinn Launches Fully Integrated Targeted Therapy (FITT) Strategy and Announces Leadership and Structural Changes Strategy focuses on developing and commercializing a differentiated pipeline of...